| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
159,588 |
261,929 |
319,053 |
656,089 |
| Total Sell Value |
$13,270,852 |
$22,448,451 |
$27,661,182 |
$61,420,002 |
| Total People Sold |
5 |
6 |
7 |
7 |
| Total Sell Transactions |
10 |
20 |
27 |
56 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Aselage Steve |
SVP, Global Commercial Dev. |
• – – |
2008-05-02 |
4 |
S |
$37.75 |
$143,450 |
D/D |
(3,800) |
44,865 |
|
- |
|
| Aselage Steve |
SVP, Global Commercial Dev. |
• – – |
2008-05-02 |
4 |
OE |
$7.16 |
$20,764 |
D/D |
2,900 |
36,460 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2008-05-02 |
4 |
AS |
$36.50 |
$376,050 |
D/D |
(10,100) |
8,567 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2008-05-02 |
4 |
OE |
$6.46 |
$64,600 |
D/D |
10,000 |
21,120 |
|
- |
|
| Kakkis Emil D |
Chief Medical Officer |
• – – |
2008-05-01 |
4 |
AS |
$37.31 |
$674,857 |
D/D |
(18,000) |
162,804 |
|
- |
|
| Kakkis Emil D |
Chief Medical Officer |
• – – |
2008-05-01 |
4 |
OE |
$4.00 |
$72,000 |
D/D |
18,000 |
180,804 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2008-05-01 |
4 |
AS |
$36.00 |
$275,069 |
D/D |
(7,453) |
18,667 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2008-05-01 |
4 |
OE |
$6.46 |
$32,300 |
D/D |
5,000 |
11,120 |
|
- |
|
| Kakkis Emil D |
Chief Medical Officer |
• – – |
2008-04-30 |
4 |
AB |
$10.37 |
$17,007 |
D/D |
1,640 |
162,804 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-04-30 |
4 |
AB |
$10.37 |
$18,189 |
D/D |
1,754 |
36,434 |
|
- |
|
| Davis George Eric |
VP, General Counsel |
• – – |
2008-04-30 |
4 |
AS |
$35.52 |
$166,960 |
D/D |
(4,600) |
6,207 |
|
- |
|
| Davis George Eric |
VP, General Counsel |
• – – |
2008-04-30 |
4 |
OE |
$7.84 |
$39,200 |
D/D |
5,000 |
10,807 |
|
- |
|
| Davis George Eric |
VP, General Counsel |
• – – |
2008-04-30 |
4 |
AB |
$10.37 |
$18,770 |
D/D |
1,810 |
5,807 |
|
- |
|
| Cooper Jeffrey H |
SVP, Chief Financial Officer |
• – – |
2008-04-30 |
4 |
B |
$13.95 |
$14,925 |
D/D |
1,070 |
2,075 |
2.74 |
- |
|
| Aselage Steve |
SVP, Global Commercial Dev. |
• – – |
2008-04-30 |
4 |
B |
$10.37 |
$15,825 |
D/D |
1,526 |
33,560 |
2.74 |
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2008-04-30 |
4 |
AB |
$10.37 |
$21,248 |
D/D |
2,049 |
6,120 |
|
- |
|
| Davis George Eric |
VP, General Counsel |
• – – |
2008-04-30 |
4 |
AS |
$36.68 |
$14,693 |
D/D |
(400) |
5,807 |
|
- |
|
| Kakkis Emil D |
Chief Medical Officer |
• – – |
2008-04-29 |
4 |
OE |
$4.00 |
$300,000 |
D/D |
75,000 |
161,164 |
|
- |
|
| Wood Mark |
VP, Human Resources |
• – – |
2008-04-21 |
4 |
AS |
$33.79 |
$101,635 |
D/D |
(2,990) |
0 |
|
- |
|
| Wood Mark |
VP, Human Resources |
• – – |
2008-04-21 |
4 |
OE |
$6.13 |
$40,344 |
D/D |
2,990 |
2,990 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-04-02 |
4 |
AS |
$36.66 |
$847,049 |
D/D |
(22,965) |
50,477 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-04-02 |
4 |
OE |
$6.13 |
$276,343 |
D/D |
38,762 |
73,442 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-04-02 |
4 |
AS |
$37.02 |
$586,299 |
D/D |
(15,797) |
34,680 |
|
- |
|
| Kakkis Emil D |
Chief Medical Officer |
• – – |
2008-04-01 |
4 |
AS |
$35.65 |
$291,120 |
D/D |
(8,143) |
96,021 |
|
- |
|
| Kakkis Emil D |
Chief Medical Officer |
• – – |
2008-04-01 |
4 |
OE |
$4.00 |
$72,000 |
D/D |
18,000 |
104,164 |
|
- |
|
1303 Records found
|
|
Page 43 of 53 |
|
|
1.44 (1.6%) 
